HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintained a $22 price target.
August 13, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Y-mAbs Therapeutics and maintained a $22 price target.
The reiteration of a Buy rating and the maintenance of a $22 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100